<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="375">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01346267</url>
  </required_header>
  <id_info>
    <org_study_id>SCUSF 1202</org_study_id>
    <secondary_id>SCUSF-1202</secondary_id>
    <secondary_id>COG-ACCL1032</secondary_id>
    <secondary_id>5U10CA081920</secondary_id>
    <nct_id>NCT01346267</nct_id>
  </id_info>
  <brief_title>Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy</brief_title>
  <acronym>SCUSF1202</acronym>
  <official_title>Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>United States: Federal Government</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Acupressure wristbands may prevent or reduce nausea and caused by chemotherapy.
      It is not yet known whether standard care is more effective with or without acupressure
      wristbands in controlling acute and delayed nausea.

      PURPOSE: This randomized phase III trial is studying how well acupressure wristbands work
      with or without standard care in controlling nausea in young patients receiving highly
      emetogenic chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To compare the control of chemotherapy-induced nausea (CIN) in the acute phase provided
           by a 5-HT3 antagonist combined with acupressure versus placebo acupressure in children
           4 to 18 years of age being treated with chemotherapy including cisplatin ≥ 50
           mg/m2/dose, ifosfamide plus etoposide/doxorubicin, or cyclophosphamide plus an
           anthracycline.

      Secondary

        -  To compare the control of CIN in the delayed phase provided by a 5-HT3 antagonist
           combined with acupressure versus placebo acupressure in children 4 to 18 years of age
           being treated with chemotherapy including cisplatin ≥ 50 mg/m2/dose, ifosfamide plus
           etoposide/doxorubicin, or cyclophosphamide plus an anthracycline.

        -  To compare the control of chemotherapy-induced vomiting and retching (CIV) in the acute
           and delayed phases provided by a 5-HT3 antagonist combined with acupressure versus
           placebo acupressure in children 4 to 18 years of age being treated with chemotherapy
           including cisplatin ≥ 50 mg/m2/dose, ifosfamide plus etoposide/doxorubicin, or
           cyclophosphamide plus an anthracycline.

      OUTLINE: This is a multicenter study. Patients are stratified according chemotherapy regimen
      and anti-emetic Regimen 5-HT3 agonists (ondansetron or granisetron.) Patients are randomized
      to 1 of 2 treatment arms.

        -  Arm I: Patients wear Sea-Band acupressure wristbands on each wrist beginning
           approximately 30 minutes prior to the first cisplatin-containing chemotherapy course
           and continually for 24 hours after the last chemotherapy dose (acute phase), and for a
           maximum of 7 days or until the next chemotherapy course starts (delayed phase).
           Patients are allowed to take bands off intermittently (up to 4 times a day, for no more
           than 15 minutes each time) to relieve pressure or to bathe. Patients also receive
           standard of care anti-emetic prophylaxis comprising granisetron, ondansetron, or
           dexamethasone during chemotherapy according to institutional or physician preference.

        -  Arm II: Patients wear placebo wristbands on each wrist and receive standard of care
           anti-emetic prophylaxis during chemotherapy as patients in arm I.

      Patients, parents, or guardians are instructed to complete an impatient and an outpatient
      diaries on nausea severity and the time of each emetic episode. Patients, parents, or
      guardians also complete a questionnaire about acupressure at the end of the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2011</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Control of CIN during acute phase of chemotherapy</measure>
    <time_frame>Each day of Chemotherapy course.  Maximum of 7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Acute Phase - bands will be worn on each day of the chemotherapy course and for 24 hours after the last chemotherapy dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Control of CIN during delayed phase of chemotherapy</measure>
    <time_frame>Maximum of 7 days after Acute Phase</time_frame>
    <safety_issue>No</safety_issue>
    <description>Delayed Phase - Bands will continue to be worn for a maximum of 7 days or until the next chemotherapy cycle starts, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of CIN during acute and delayed phase of chemotherapy</measure>
    <time_frame>Maximum of 14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total Duration of Study includes both acute and delayed phases.
Acute Phase - bands will be worn on each day of the chemotherapy course and for 24 hours after the last chemotherapy dose
Delayed Phase - Bands will continue to be worn for a maximum of 7 days or until the next chemotherapy cycle starts, whichever comes first.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Central Nervous System Tumor, Pediatric</condition>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I- Real Acupressure bands</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients wear  Sea-Band  acupressure wristbands on each wrist beginning approximately  30 minutes prior to the first  cisplatin-containing chemotherapy course and continually for 24 hours after the last  chemotherapy dose (acute phase), and for a maximum of 7 days  or until the next chemotherapy course starts (delayed phase). Patients are allowed to take bands off intermittently (up to 4 times a day, for no more than 15 minutes each time) to relieve pressure or to bathe. Patients  also receive standard of care anti-emetic prophylaxis comprising   granisetron, ondansetron, or dexamethasone during chemotherapy according to institutional or physician preference.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II- Placebo Acupressure Bands</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients wear  placebo wristbands  on each  wrist  and receive standard of care anti-emetic prophylaxis  during chemotherapy as patients in arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Real Acupressure Band</intervention_name>
    <description>Acupressure wristband</description>
    <arm_group_label>Arm I- Real Acupressure bands</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placebo Acupressure Band</intervention_name>
    <description>Sham wristband</description>
    <arm_group_label>Arm II- Placebo Acupressure Bands</arm_group_label>
    <other_name>sham intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  4 to 18 years of age, inclusive.  The patient's cognitive ability must be considered
             by a parent or healthcare professional to be at least at a 4 year-old level.

          -  Newly diagnosed (i.e., not relapsed) with any malignancy.

          -  Patients are not required to be registered on a COG therapeutic trial.

          -  The patient's current chemotherapy treatment plan must include at least 1 course of

               -  cisplatin at ≥ 50 mg/m2/dose  or

               -  ifosfamide plus etoposide or doxorubicin or

               -  cyclophosphamide plus an anthracycline.

          -  Patients may have previously received other chemotherapy.

          -  The patient's current treatment plan must include an anti-emetic regimen with either
             ondansetron or granisetron on a scheduled basis. Patients may also receive
             dexamethasone for antiemetic prophylaxis during the acute phase at the discretion of
             the treating physician.  Patients  ≥ 12 years old may also receive aprepitant in
             conjunction with dexamethasone for antiemetic prophylaxis at the discretion of the
             treating physician.

          -  Patients needing anti-emetic treatment for breakthrough nausea/vomiting may also
             receive anti-emetic agents on an as needed (PRN) basis.

          -  The patient (parent/guardian) must be English-speaking (i.e., able to read and speak
             in English) since the PeNAT has been validated only in English.

          -  All patients and/or their parents or legal guardians must sign a written informed
             consent (patient assent is also recommended when applicable according to each
             institution's policy).

        EXCLUSION CRITERIA:

          -  Prior history of acupressure use.

          -  Scheduled use of antiemetic agents other than ondansetron, granisetron, dexamethasone
              or aprepitant.  Patients may receive other antiemetic agents PRN for breakthrough
             nausea/vomiting but not on a scheduled basis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Williams McLean, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Comprehensive Cancer Center of Wake Forest University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lee Dupuis, MScPhm</last_name>
    <role>Study Chair</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Miller Children's Hospital</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Devin Murphy, MSW</last_name>
      <phone>562-933-8626</phone>
      <email>dmurphy@memorialcare.org</email>
    </contact>
    <investigator>
      <last_name>Amanda Termuhlen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Reichman</last_name>
      <phone>323-361-5973</phone>
      <email>lreichman@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Kelley Haley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Ruiz</last_name>
      <phone>860-837-5877</phone>
      <email>truiz@ccmckids.org</email>
    </contact>
    <investigator>
      <last_name>Michael Isakoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Southwest Florida at Lee Memorial</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Arnstrom</last_name>
      <phone>239-343-6959</phone>
    </contact>
    <investigator>
      <last_name>Emad Salman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Ingram, RN, BSN</last_name>
      <phone>904-697-3985</phone>
      <email>iingram@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Eric Sandler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Gibbs</last_name>
      <phone>407-650-7230</phone>
    </contact>
    <investigator>
      <last_name>Ramamoorthy Nagasubramanian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dannah McCormick</last_name>
      <phone>850-505-4794</phone>
      <email>Dannah.McCormick@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Repp</last_name>
      <phone>727-767-4784</phone>
      <email>AshleyRepp@allkids.org</email>
    </contact>
    <investigator>
      <last_name>Gregory Hale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Amiotte</last_name>
      <phone>808-983-6386</phone>
      <email>annette.amiotte@hawaiipacifichealth.org</email>
    </contact>
    <investigator>
      <last_name>Robert Wilkinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa Forschler, RN</last_name>
      <phone>504-842-3903</phone>
      <email>mforschler@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Craig Lotterman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute at Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Ellis</last_name>
      <phone>617-632-4595</phone>
    </contact>
    <investigator>
      <last_name>Nicole Ullrich, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margie Negron</last_name>
      <phone>212-305-8630</phone>
    </contact>
    <investigator>
      <last_name>Elena Ladas, PhD, RD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graham Keyes</last_name>
      <phone>336-716-9027</phone>
    </contact>
    <investigator>
      <last_name>Thomas McLean, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trish Ahrens</last_name>
      <phone>419-251-8075</phone>
    </contact>
    <investigator>
      <last_name>Rama Jasty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Randall Children's Hospital at Legacy Emanuel</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Rashko, CCRP</last_name>
      <phone>503-276-9376</phone>
    </contact>
    <investigator>
      <last_name>Janice F Olson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRISTUS Santa Rosa Children's Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Garcia</last_name>
      <phone>210-567-7461</phone>
      <email>garciaj29@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Anne-Marie Langevin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113-1100</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Clawson, BA</last_name>
      <phone>801-662-4715</phone>
      <email>jason.clawson@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Phillip Barnette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Entela Zaffino</last_name>
      <phone>416-813-5055</phone>
    </contact>
    <investigator>
      <last_name>Lillian Sung</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lee Dupuis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <link>
    <url>http://cancer.gov/clinicaltrials/SCUSF-1202</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>July 30, 2013</lastchanged_date>
  <firstreceived_date>April 29, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nausea and vomiting</keyword>
  <keyword>unspecified childhood solid tumor</keyword>
  <keyword>childhood central nervous system embryonal tumor</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>childhood central nervous system germinoma</keyword>
  <keyword>childhood central nervous system mixed germ cell tumor</keyword>
  <keyword>childhood central nervous system teratoma</keyword>
  <keyword>childhood central nervous system yolk sac tumor</keyword>
  <keyword>childhood mixed glioma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>untreated childhood brain stem glioma</keyword>
  <keyword>untreated childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>untreated childhood visual pathway glioma</keyword>
  <keyword>childhood high-grade cerebellar astrocytoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>childhood low-grade cerebellar astrocytoma</keyword>
  <keyword>childhood low-grade cerebral astrocytoma</keyword>
  <keyword>untreated childhood cerebellar astrocytoma</keyword>
  <keyword>untreated childhood cerebral astrocytoma</keyword>
  <keyword>untreated childhood subependymal giant cell astrocytoma</keyword>
  <keyword>childhood ependymoblastoma</keyword>
  <keyword>untreated childhood medulloblastoma</keyword>
  <keyword>untreated childhood pineoblastoma</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood craniopharyngioma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>childhood medulloepithelioma</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>newly diagnosed childhood ependymoma</keyword>
  <keyword>childhood meningioma</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Emetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
